Review





Similar Products

apc-labeled h-2kb/p15e(604-611)-tetramer  (MBL Life science)
90
MBL Life science apc-labeled h-2kb/p15e(604-611)-tetramer
Apc Labeled H 2kb/P15e(604 611) Tetramer, supplied by MBL Life science, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/p15e/t+select+h+2kb+ova+tetramer+siinfekl+pe/pmc09840123__mmc1-123-8-10
Average 90 stars, based on 1 article reviews
apc-labeled h-2kb/p15e(604-611)-tetramer - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
rat anti mlv transmembrane protein p15e  (Absolute Biotech Inc)
86
Absolute Biotech Inc rat anti mlv transmembrane protein p15e
Rat Anti Mlv Transmembrane Protein P15e, supplied by Absolute Biotech Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/p15e/anti+mlv+p15e+protein+rat+transmembrane/bio_rxiv__2024__12__06__627204-341-43-49
Average 86 stars, based on 1 article reviews
rat anti mlv transmembrane protein p15e - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
h-2kb mulv p15e tetramer-kspwfttl-apc  (MBL International)
90
MBL International h-2kb mulv p15e tetramer-kspwfttl-apc
Aging reduces the proportions and numbers of tumor antigen–specific cytotoxic CD8 + T cells. A–C, Representative flow cytometry contour plots depicting staining of intratumoral OVA-specific CD8 + T cells from young or aged mice in the MC38-OVA ( A ), B16-OVA ( B ), and EO771-OVA ( C ) tumor models at day 12 after tumor cell implantation. D and E, Quantification of the percentage ( D ) [(B16-OVA young, n = 15; aged, n = 15), (MC38-OVA young, n = 15; aged, n = 10), (EO771-OVA young, n = 15; aged, n = 14) and absolute numbers ( E ) [(B16-OVA young, n = 15; aged, n = 14), (MC38-OVA young, n = 15; aged, n = 10), (EO771-OVA young, n = 15; aged, n = 14)] of intratumoral SIINFEKL-reactive CD8 + T cells from young or aged mice in the MC38-OVA, B16-OVA, and EO771-OVA tumor models at day 12. F and G, Quantification of the percentage ( F ) and absolute numbers ( G ) of melanoma tumor-associated antigen-specific CD8 + T cells including MuLV <t>p15E,</t> gp100, and TRP-2 antigen-specific T cells from young or aged mice bearing B16-OVA tumors at day 12 after tumor cell implantation (young, n = 16; aged n = 16). Results are representative of at least two independent experiments per tumor model ( A–C ). Statistical significance was assessed by Student t test ( D–G ). Results represent a pool of two independent experiments ( D–G ). Each dot represents an individual animal. Graphs display mean ± SD ( D–G ). *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001.
H 2kb Mulv P15e Tetramer Kspwfttl Apc, supplied by MBL International, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/p15e/h+2kb+mulv+p15e+tetramer/pmc11532741-69-106-110
Average 90 stars, based on 1 article reviews
h-2kb mulv p15e tetramer-kspwfttl-apc - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
h-2k b mulv p15e tetramer-kspwfttl  (MBL International)
90
MBL International h-2k b mulv p15e tetramer-kspwfttl
Aging reduces the proportions and numbers of tumor antigen–specific cytotoxic CD8 + T cells. A–C, Representative flow cytometry contour plots depicting staining of intratumoral OVA-specific CD8 + T cells from young or aged mice in the MC38-OVA ( A ), B16-OVA ( B ), and EO771-OVA ( C ) tumor models at day 12 after tumor cell implantation. D and E, Quantification of the percentage ( D ) [(B16-OVA young, n = 15; aged, n = 15), (MC38-OVA young, n = 15; aged, n = 10), (EO771-OVA young, n = 15; aged, n = 14) and absolute numbers ( E ) [(B16-OVA young, n = 15; aged, n = 14), (MC38-OVA young, n = 15; aged, n = 10), (EO771-OVA young, n = 15; aged, n = 14)] of intratumoral SIINFEKL-reactive CD8 + T cells from young or aged mice in the MC38-OVA, B16-OVA, and EO771-OVA tumor models at day 12. F and G, Quantification of the percentage ( F ) and absolute numbers ( G ) of melanoma tumor-associated antigen-specific CD8 + T cells including MuLV <t>p15E,</t> gp100, and TRP-2 antigen-specific T cells from young or aged mice bearing B16-OVA tumors at day 12 after tumor cell implantation (young, n = 16; aged n = 16). Results are representative of at least two independent experiments per tumor model ( A–C ). Statistical significance was assessed by Student t test ( D–G ). Results represent a pool of two independent experiments ( D–G ). Each dot represents an individual animal. Graphs display mean ± SD ( D–G ). *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001.
H 2k B Mulv P15e Tetramer Kspwfttl, supplied by MBL International, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/p15e/h+2kb+mulv+p15e+tetramer/pmc11496807-365-10-19
Average 90 stars, based on 1 article reviews
h-2k b mulv p15e tetramer-kspwfttl - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
p15e tetramer  (MBL Life science)
90
MBL Life science p15e tetramer
Aging reduces the proportions and numbers of tumor antigen–specific cytotoxic CD8 + T cells. A–C, Representative flow cytometry contour plots depicting staining of intratumoral OVA-specific CD8 + T cells from young or aged mice in the MC38-OVA ( A ), B16-OVA ( B ), and EO771-OVA ( C ) tumor models at day 12 after tumor cell implantation. D and E, Quantification of the percentage ( D ) [(B16-OVA young, n = 15; aged, n = 15), (MC38-OVA young, n = 15; aged, n = 10), (EO771-OVA young, n = 15; aged, n = 14) and absolute numbers ( E ) [(B16-OVA young, n = 15; aged, n = 14), (MC38-OVA young, n = 15; aged, n = 10), (EO771-OVA young, n = 15; aged, n = 14)] of intratumoral SIINFEKL-reactive CD8 + T cells from young or aged mice in the MC38-OVA, B16-OVA, and EO771-OVA tumor models at day 12. F and G, Quantification of the percentage ( F ) and absolute numbers ( G ) of melanoma tumor-associated antigen-specific CD8 + T cells including MuLV <t>p15E,</t> gp100, and TRP-2 antigen-specific T cells from young or aged mice bearing B16-OVA tumors at day 12 after tumor cell implantation (young, n = 16; aged n = 16). Results are representative of at least two independent experiments per tumor model ( A–C ). Statistical significance was assessed by Student t test ( D–G ). Results represent a pool of two independent experiments ( D–G ). Each dot represents an individual animal. Graphs display mean ± SD ( D–G ). *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001.
P15e Tetramer, supplied by MBL Life science, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/p15e/t+select+h+2kb+ova+tetramer+siinfekl+pe/pm39112631-322-0-2
Average 90 stars, based on 1 article reviews
p15e tetramer - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
h-2kb mulv p15e tetramer  (MBL Life science)
90
MBL Life science h-2kb mulv p15e tetramer
Aging reduces the proportions and numbers of tumor antigen–specific cytotoxic CD8 + T cells. A–C, Representative flow cytometry contour plots depicting staining of intratumoral OVA-specific CD8 + T cells from young or aged mice in the MC38-OVA ( A ), B16-OVA ( B ), and EO771-OVA ( C ) tumor models at day 12 after tumor cell implantation. D and E, Quantification of the percentage ( D ) [(B16-OVA young, n = 15; aged, n = 15), (MC38-OVA young, n = 15; aged, n = 10), (EO771-OVA young, n = 15; aged, n = 14) and absolute numbers ( E ) [(B16-OVA young, n = 15; aged, n = 14), (MC38-OVA young, n = 15; aged, n = 10), (EO771-OVA young, n = 15; aged, n = 14)] of intratumoral SIINFEKL-reactive CD8 + T cells from young or aged mice in the MC38-OVA, B16-OVA, and EO771-OVA tumor models at day 12. F and G, Quantification of the percentage ( F ) and absolute numbers ( G ) of melanoma tumor-associated antigen-specific CD8 + T cells including MuLV <t>p15E,</t> gp100, and TRP-2 antigen-specific T cells from young or aged mice bearing B16-OVA tumors at day 12 after tumor cell implantation (young, n = 16; aged n = 16). Results are representative of at least two independent experiments per tumor model ( A–C ). Statistical significance was assessed by Student t test ( D–G ). Results represent a pool of two independent experiments ( D–G ). Each dot represents an individual animal. Graphs display mean ± SD ( D–G ). *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001.
H 2kb Mulv P15e Tetramer, supplied by MBL Life science, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/p15e/t+select+h+2kb+ova+tetramer+siinfekl+pe/pmc11292205-102-19-25
Average 90 stars, based on 1 article reviews
h-2kb mulv p15e tetramer - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
rat anti-mlv p15e 42/114  (Absolute Biotech Inc)
90
Absolute Biotech Inc rat anti-mlv p15e 42/114
Aging reduces the proportions and numbers of tumor antigen–specific cytotoxic CD8 + T cells. A–C, Representative flow cytometry contour plots depicting staining of intratumoral OVA-specific CD8 + T cells from young or aged mice in the MC38-OVA ( A ), B16-OVA ( B ), and EO771-OVA ( C ) tumor models at day 12 after tumor cell implantation. D and E, Quantification of the percentage ( D ) [(B16-OVA young, n = 15; aged, n = 15), (MC38-OVA young, n = 15; aged, n = 10), (EO771-OVA young, n = 15; aged, n = 14) and absolute numbers ( E ) [(B16-OVA young, n = 15; aged, n = 14), (MC38-OVA young, n = 15; aged, n = 10), (EO771-OVA young, n = 15; aged, n = 14)] of intratumoral SIINFEKL-reactive CD8 + T cells from young or aged mice in the MC38-OVA, B16-OVA, and EO771-OVA tumor models at day 12. F and G, Quantification of the percentage ( F ) and absolute numbers ( G ) of melanoma tumor-associated antigen-specific CD8 + T cells including MuLV <t>p15E,</t> gp100, and TRP-2 antigen-specific T cells from young or aged mice bearing B16-OVA tumors at day 12 after tumor cell implantation (young, n = 16; aged n = 16). Results are representative of at least two independent experiments per tumor model ( A–C ). Statistical significance was assessed by Student t test ( D–G ). Results represent a pool of two independent experiments ( D–G ). Each dot represents an individual animal. Graphs display mean ± SD ( D–G ). *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001.
Rat Anti Mlv P15e 42/114, supplied by Absolute Biotech Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/p15e/rat+anti+mlv+p15e+42+114/pm39074162-474-11-16
Average 90 stars, based on 1 article reviews
rat anti-mlv p15e 42/114 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
h-2k b -restricted mulv p15e kspwfttl peptide (ksp  (MBL Life science)
90
MBL Life science h-2k b -restricted mulv p15e kspwfttl peptide (ksp
Aging reduces the proportions and numbers of tumor antigen–specific cytotoxic CD8 + T cells. A–C, Representative flow cytometry contour plots depicting staining of intratumoral OVA-specific CD8 + T cells from young or aged mice in the MC38-OVA ( A ), B16-OVA ( B ), and EO771-OVA ( C ) tumor models at day 12 after tumor cell implantation. D and E, Quantification of the percentage ( D ) [(B16-OVA young, n = 15; aged, n = 15), (MC38-OVA young, n = 15; aged, n = 10), (EO771-OVA young, n = 15; aged, n = 14) and absolute numbers ( E ) [(B16-OVA young, n = 15; aged, n = 14), (MC38-OVA young, n = 15; aged, n = 10), (EO771-OVA young, n = 15; aged, n = 14)] of intratumoral SIINFEKL-reactive CD8 + T cells from young or aged mice in the MC38-OVA, B16-OVA, and EO771-OVA tumor models at day 12. F and G, Quantification of the percentage ( F ) and absolute numbers ( G ) of melanoma tumor-associated antigen-specific CD8 + T cells including MuLV <t>p15E,</t> gp100, and TRP-2 antigen-specific T cells from young or aged mice bearing B16-OVA tumors at day 12 after tumor cell implantation (young, n = 16; aged n = 16). Results are representative of at least two independent experiments per tumor model ( A–C ). Statistical significance was assessed by Student t test ( D–G ). Results represent a pool of two independent experiments ( D–G ). Each dot represents an individual animal. Graphs display mean ± SD ( D–G ). *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001.
H 2k B Restricted Mulv P15e Kspwfttl Peptide (Ksp, supplied by MBL Life science, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/p15e/t+select+h+2kb+ova+tetramer+siinfekl+pe/pmc11080179-60-5-15
Average 90 stars, based on 1 article reviews
h-2k b -restricted mulv p15e kspwfttl peptide (ksp - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
e-mimotope p15e-3c2v  (Mimotopes)
90
Mimotopes e-mimotope p15e-3c2v
Aging reduces the proportions and numbers of tumor antigen–specific cytotoxic CD8 + T cells. A–C, Representative flow cytometry contour plots depicting staining of intratumoral OVA-specific CD8 + T cells from young or aged mice in the MC38-OVA ( A ), B16-OVA ( B ), and EO771-OVA ( C ) tumor models at day 12 after tumor cell implantation. D and E, Quantification of the percentage ( D ) [(B16-OVA young, n = 15; aged, n = 15), (MC38-OVA young, n = 15; aged, n = 10), (EO771-OVA young, n = 15; aged, n = 14) and absolute numbers ( E ) [(B16-OVA young, n = 15; aged, n = 14), (MC38-OVA young, n = 15; aged, n = 10), (EO771-OVA young, n = 15; aged, n = 14)] of intratumoral SIINFEKL-reactive CD8 + T cells from young or aged mice in the MC38-OVA, B16-OVA, and EO771-OVA tumor models at day 12. F and G, Quantification of the percentage ( F ) and absolute numbers ( G ) of melanoma tumor-associated antigen-specific CD8 + T cells including MuLV <t>p15E,</t> gp100, and TRP-2 antigen-specific T cells from young or aged mice bearing B16-OVA tumors at day 12 after tumor cell implantation (young, n = 16; aged n = 16). Results are representative of at least two independent experiments per tumor model ( A–C ). Statistical significance was assessed by Student t test ( D–G ). Results represent a pool of two independent experiments ( D–G ). Each dot represents an individual animal. Graphs display mean ± SD ( D–G ). *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001.
E Mimotope P15e 3c2v, supplied by Mimotopes, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/p15e/p15e+3c+mimotope/pmc10986479-246-15-3
Average 90 stars, based on 1 article reviews
e-mimotope p15e-3c2v - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


Aging reduces the proportions and numbers of tumor antigen–specific cytotoxic CD8 + T cells. A–C, Representative flow cytometry contour plots depicting staining of intratumoral OVA-specific CD8 + T cells from young or aged mice in the MC38-OVA ( A ), B16-OVA ( B ), and EO771-OVA ( C ) tumor models at day 12 after tumor cell implantation. D and E, Quantification of the percentage ( D ) [(B16-OVA young, n = 15; aged, n = 15), (MC38-OVA young, n = 15; aged, n = 10), (EO771-OVA young, n = 15; aged, n = 14) and absolute numbers ( E ) [(B16-OVA young, n = 15; aged, n = 14), (MC38-OVA young, n = 15; aged, n = 10), (EO771-OVA young, n = 15; aged, n = 14)] of intratumoral SIINFEKL-reactive CD8 + T cells from young or aged mice in the MC38-OVA, B16-OVA, and EO771-OVA tumor models at day 12. F and G, Quantification of the percentage ( F ) and absolute numbers ( G ) of melanoma tumor-associated antigen-specific CD8 + T cells including MuLV p15E, gp100, and TRP-2 antigen-specific T cells from young or aged mice bearing B16-OVA tumors at day 12 after tumor cell implantation (young, n = 16; aged n = 16). Results are representative of at least two independent experiments per tumor model ( A–C ). Statistical significance was assessed by Student t test ( D–G ). Results represent a pool of two independent experiments ( D–G ). Each dot represents an individual animal. Graphs display mean ± SD ( D–G ). *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001.

Journal: Cancer Immunology Research

Article Title: Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity

doi: 10.1158/2326-6066.CIR-24-0463

Figure Lengend Snippet: Aging reduces the proportions and numbers of tumor antigen–specific cytotoxic CD8 + T cells. A–C, Representative flow cytometry contour plots depicting staining of intratumoral OVA-specific CD8 + T cells from young or aged mice in the MC38-OVA ( A ), B16-OVA ( B ), and EO771-OVA ( C ) tumor models at day 12 after tumor cell implantation. D and E, Quantification of the percentage ( D ) [(B16-OVA young, n = 15; aged, n = 15), (MC38-OVA young, n = 15; aged, n = 10), (EO771-OVA young, n = 15; aged, n = 14) and absolute numbers ( E ) [(B16-OVA young, n = 15; aged, n = 14), (MC38-OVA young, n = 15; aged, n = 10), (EO771-OVA young, n = 15; aged, n = 14)] of intratumoral SIINFEKL-reactive CD8 + T cells from young or aged mice in the MC38-OVA, B16-OVA, and EO771-OVA tumor models at day 12. F and G, Quantification of the percentage ( F ) and absolute numbers ( G ) of melanoma tumor-associated antigen-specific CD8 + T cells including MuLV p15E, gp100, and TRP-2 antigen-specific T cells from young or aged mice bearing B16-OVA tumors at day 12 after tumor cell implantation (young, n = 16; aged n = 16). Results are representative of at least two independent experiments per tumor model ( A–C ). Statistical significance was assessed by Student t test ( D–G ). Results represent a pool of two independent experiments ( D–G ). Each dot represents an individual animal. Graphs display mean ± SD ( D–G ). *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001.

Article Snippet: The following antibodies were used: BUV395 Hamster Anti-Mouse TCRβ Chain (BD Biosciences, Clone H57-597), BUV661 Rat Anti-Mouse CD45 (BD Biosciences, Clone 30-F11), BUV496 Rat-Anti-Mouse CD4 (BD Biosciences, Clone GK1.5), BUV805 Rat Anti-Mouse CD8α (BD Biosciences, Clone 53-6.7), eFluor450 Anti-Mouse Foxp3 (Ebioscience, Clone FJK-16s), Brilliant Violet 510 Anti-Mouse PD-1 (Biolegend, Clone 29F.1A12), Brilliant Violet 605 Rat Anti-Mouse CD62L (Biolegend, Clone MEL-14), Brilliant Violet 711 Anti-Mouse CD366 (Biolegend, Clone RMT3-23), Brilliant Violet 785 Anti-Mouse CD44 (Biolegend, Clone IM7), Alexa Flour 488 Mouse Anti-TCF-7/TCF-1 (BD Biosciences, Clone S33-966), PerCP-Cy5.5 Mouse Anti-Ki-67 (BD Biosciences, Clone B56), PE/Cyanine7 Anti-T-bet (Biolegend, Clone 4B10), Alexa Flour 700 Anti-human/mouse Granzyme-B (GZMB; Biolegend, Clone QA16A02), H-2Kb MuLV p15E Tetramer-KSPWFTTL-APC (MBL International, TB-M507-2), Tetramer/BV421 - H-2Kb TRP2 SVYDFFVWL (MBL International, TB-5004-4), H-2Db gp100 Tetramer-EGSRNQDWL-PE (MBL International, TS-M546-1), BUV395 Anti-Mouse TCR Vβ3 (BD Biosciences, Clone KJ25), BUV496 Anti-Mouse TCR Vβ5.1/5.2 (BD Biosciences, Clone MR9-4), BUV563 Anti-Mouse CD44 (BD Biosciences, Clone IM7), BUV661 Anti-Mouse TCR Vβ12 (BD Biosciences, Clone MR11-1), BUV737 Anti-Mouse TCR Vβ8.1/8.2 (BD Biosciences, Clone MR5-2), BUV805 Anti-Mouse TCR Vβ10b (BD Biosciences, Clone B21.5), BV421 Anti-Mouse TCR Vβ14 (BD Biosciences, Clone 14-2), BV605 Anti-Mouse TCR Vβ4 (BD Biosciences, Clone KT4), BV650 Anti-Mouse TCR Vβ6 (BD Biosciences, Clone RR4-7), BV711 Anti-Mouse TCR Vβ9 (BD Biosciences, Clone MR10-2), BV750 Anti-Mouse CD3 (BD Biosciences, Clone 145-2C11), BV786 Anti-Mouse TCR Vβ11 (BD Biosciences, Clone RR3-15), FITC Anti-Mouse TCR Vβ7 (BD Biosciences, Clone TR310), RB780 Anti-Mouse CD62L (BD Biosciences, Clone MEL-17), PE Anti-Mouse TCR Vβ8.3 (BD Biosciences, Clone 1B3.3), PE/Fire 700 Anti-Mouse CD4 (BD Biosciences, Clone GK1.5-5), APC Anti-Mouse CD8 (BD Biosciences, Clone 53-6.7), R718 Anti-Mouse TCR Vβ13 (BD Biosciences, Clone MR12-3), and APC-Cy7 Anti-Mouse CD45 (BD Biosciences, Clone 30-F11).

Techniques: Flow Cytometry, Staining